6 month supply of tirzepatide Compounded (GLP-1/GIP) Compounded Tirzepatide (GLP-1/GIP) 6 Months

Boehringer Ingelheim describes it as a dual glucagon/GLP1 receptor agonist that has the potential to address obesity while also supporting liver function, a key regulator of metabolic health. The company links the waistcircumference reduction in SYNCHRONIZE1 to effects on visceral fat, noting that excess visceral fat, particularly abdominal, is a known contributor to metabolic dysfunction and closely connected to impaired liver function

Accordingly, DPP-4 may influence metabolic control indirectly by modulating PYY effects on food intake and body weight

Labels advise stopping if suspected and avoiding use in those with a history of pancreatitis

These powerful medications have revolutionized treatment for type 2 diabetes and weight management, but they can also slow down your digestive system, leading to constipation and other gastrointestinal issues

K.ManleyG

( B ) Volcano plot showing genes that are differentially regulated in the -1 subcluster upon liraglutide treatment